866-997-4948(US-Canada Toll Free)

Letairis/Volibris (ambrisentan) - Analysis and Forecasts from 2007 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 38 Pages


GlobalDatas pharmaceuticals report, Letairis/Volibris (ambrisentan) Analysis and Forecasts from 2007 to 2020 provides Letairis sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Letairis including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Letairis including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Letairis in the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Pulmonary Arterial Hypertension 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 4
2.3 Etiology 5
2.3.1 Scleroderma 5
2.3.2 Sickle Cell Disease 5
2.3.3 HIV/AIDS 5
2.3.4 Drug Abuse and Toxins 5
2.4 Economic Impact of PAH 5
2.5 GlobalData Report Guidance 5

3 Pulmonary Arterial Hypertension (PAH): Market Characterization 7
3.1 PAH Market 7
3.2 PAH Market Forecasts and CAGR 8
3.3 PAH Market : Drivers and Restraints 8
3.3.1 Drivers 9
3.3.2 Barriers 10

4 Classification of PAH 11
4.1 Classification Based on Cause and Clinical Presentation 11
4.1.1 Idiopathic PAH 11
4.1.2 Familial PAH 11
4.1.3 Drug Induced PAH 11
4.1.4 PAH Associated with Other Conditions 11
4.1.5 PAH Associated with Significant Venous or Capillary Involvement 11
4.2 Symptomatic Profile of PAH 11

5 Evolution of PAH Treatments 12

6 Medications 13
6.1 Prostanoids 13
6.1.1 Epoprostenol 13
6.1.2 Treprostinil 13
6.1.3 Iloprost 13
6.1.4 Beraprost 13
6.2 Endothelin Receptor Antagonists 13
6.2.1 Bosentan 13
6.2.2 Ambrisentan 14
6.2.3 Sitaxsentan 14
6.3 Phosphodiesterase Type 5 Inhibitors 14
6.3.1 Sildenafil 14
6.3.2 Tadalafil 14
6.4 Surgical Treatments 14
6.5 Investigational Combination Regimens 15
6.6 New Targets for PAH Therapy 15

7 Market Share by Class in PAH 17

8 Letairis/Volibris (ambrisentan) 18
8.1 Introduction 18
8.2 Mechanism of Action 18
8.3 Clinical Studies 18
8.4 Approval History of Letairis/Volibris 20
8.5 Factors Affecting Sales of Letairis/Volibris 20
8.5.1 Better Compliance and Dosing Convenience 20
8.5.2 Safety and Efficacy Profiles 20
8.5.3 Cost 20
8.5.4 Combination Therapy with Tadalafil 20
8.6 Drug Evaluation 21
8.6.1 Drug Risk Benefit Score 21
8.6.2 Intensity of Competition 21
8.7 Sales Estimates 22
8.7.1 Target Patient Pool of Letairis 22
8.7.2 Dosing 22
8.7.3 Market Penetration 22
8.7.4 Annual Cost of Therapy 23
8.7.5 Sales Projections of Letairis/Volibris 24

9 PAH Market: Appendix 33
9.1 Market Definitions 33
9.2 List of Abberiviations 33
9.3 Research Methodology 34
9.3.1 Coverage 34
9.3.2 Secondary Research 34
9.3.3 Forecasting 34
9.3.4 Number of Patients Approved to take the Drug 35
9.3.5 Net Penetration of Drug 35
9.3.6 Net Annual Dosing 36
9.3.7 Annual Cost of Therapy 36
9.3.8 Primary Research 36
9.3.9 Expert Panels 36
9.4 Drug Sales Estimates Model 36
9.5 Contact Us 37
9.6 Disclaimer 37
9.7 Sources 37

List of Table


Table 1: PAH, Global, Major Marketed Drugs 7
Table 2: PAH, Global, Pipeline (PhaseIII) 8
Table 3: PAH Drugs Evolution 12
Table 4: Effects of Letairis/Volibris on 6-Minute Walk Distance 19
Table 5: Incidence of Clinical Worsening 19
Table 6: Adverse Events Occurring in

List of Chart


Figure 1: PAH, Global, Market Size Forecasts ($bn), 20102020 8
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010 17
Figure 3: Drug Model Diagram of Letairis/Volibris 22
Figure 4: Letairis/Volibris, PAH, Global, Sales Estimates ($m), 20072020 24
Figure 5: Letairis, PAH, The US, Sales Estimates ($m), 20072020 25
Figure 6: Volibris, PAH, The UK, Sales Estimates ($m), 20082020 26
Figure 7: Volibris, PAH, France, Sales Estimates ($m), 20082020 27
Figure 8: Volibris, PAH, Germany, Sales Estimates ($m), 20082020 28
Figure 9: Volibris, PAH, Italy, Sales Estimates ($m), 20082020 29
Figure 10: Volibris, PAH, Spain, Sales Estimates ($m), 20082020 30
Figure 11: Volibris, PAH, Japan, Sales Estimates ($m), 20102020 31
Figure 12: Letairis/Volibris, PAH, Global, Sales Distribution by Country (%), 2015 32
Figure 13: Drug Model Diagram 35
Figure 14: Patients Approved for the Drug 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *